Tetrahydroisoquinoline derived PRMT5-inhibitors

A compound of formula I:

• wherein:
• R1 is absent, or one or more halo or methyl groups;
• R2a and R2b are independently selected from the group consisting of:
• (i) F;
• (ii) H;
• (iii) Me;
• and
• (iv) CH2OH;
• R2c and R2d are independently selected from the group consisting of:
• (i) F;
• (ii) H;
• (iii) Me;
• and
• (iv) CH2OH;
• R3a and R3b are independently selected from H and Me;
• R4 is either H or Me;
• R5 is either H or Me;
• A is either
• (i) optionally substituted phenyl;
• (ii) optionally substituted naphthyl;
• or
• (iii) optionally substituted C5-12 heteroaryl;
• wherein when A is substituted, the substituents are independently selected from the group consisting of:
• C1-4 alkyl, C1-4 fluoroalkyl, C3-6 cycloalkyl, C5-6 heteroaryl, C5-6 heteroaryl methyl, C4-6 heterocyclyl, C4-6 heterocyclyl methyl, phenyl, benzyl, halo, amido, amidomethyl, acylamido, acylamidomethyl, C1-4 alkyl ester, C1-4 alkyl ester methyl, C1-4 alkyl carbamoyl, C1 4 alkyl carbamoyl methyl, C1-4 alkylacyl, C1-4 alkylacyl methyl, phenylcarbonyl, carboxy, carboxymethyl, ether, amino, aminomethyl, sulfonamido, sulfonamino, sulfone, sulfoxide, nitrile and nitrilemethyl and when A is phenyl, the optional substituent may also be a fused C5-6 N1-containing heterocyclic ring.